WHO Issues Concern Over Critical Shortage of Weight-Loss Jabs
Fewer than one in 10 patients eligible to benefit from weight-loss injections such as Wegovy are able to get them, warns the World Health Organization as it releases its initial recommendations on the drugs.
Given in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just availability to GLP-1 medication.
Per forecasts, over two billion are projected to be living with obesity by 2030 unless action is taken.
"Our new guidance acknowledges that excess weight is a chronic disease that can be addressed with holistic and ongoing support," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are key obstacles to universal availability to the jabs that can assist patients in reducing considerable body mass, says the agency.
Skinny Jab Supply Crisis
Despite the current most favorable scenario, the manufacturing of these medications would only suffice for approximately 100 million people – fewer than 10% of eligible patients, per the health organization.
The recommendation urges nations and manufacturers to expand access, via strategies like licensing agreements.
A patent on semaglutide – the main component of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.
The Way Obesity Drugs Operate
GLP-1 drugs imitate a natural hormone to reduce digestion speed, suppress the appetite and increase feelings of fullness so individuals eat less.
Individuals typically start to lose weight in the initial weeks of starting on the weekly injections.
Studies indicates people may put most of the weight back on within a year of discontinuing the drug, when their usual food cravings resume.
Being overweight or obese raises your risk for contracting health problems, such as type 2 diabetes, heart disease, stroke, and certain malignancies.
Obesity impacts individuals in all nations and was linked to 3.7 million deaths worldwide in 2024, according to the WHO.
